Biocept to Present at Next Generation Dx Summit

SAN DIEGO, Aug. 18, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing biomarkers to improve the detection and treatment of cancer, announces that Veena Singh, M.D., Senior Vice President and Senior Medical Director of Biocept, will present "Liquid Biopsy: Providing Answers that Matter" on August 25, 2016 at the Next Generation Dx Summit being held at the Grand Hyatt Hotel in Washington, D.C.  

"Liquid biopsies allow for the identification and monitoring of validated genetic markers from tumor material that is circulating in the bloodstream," said Dr. Singh.  "Biocept's current test menu includes assays for use in six major solid tumor types including lung, gastric, breast, colorectal, prostate and melanoma that enable oncologists to treat patients based on the genetic causes of their cancer.  Biocept's Target Selector™ technology provides a non-invasive solution for physicians and their patients when a tissue biopsy is not feasible or has failed to identify a suspected cancer marker."

Highlights from Dr. Singh's presentation include the following:

• The ability to analyze both CTCs and ctDNA with Biocept's dual-platform technology
• The high-sensitivity performance of Biocept's Target Selector™ technology
• The robust clinical and analytical data validating Biocept's blood-based liquid biopsy platform

About the Next Generation Dx Summit

The Next Generation Dx Summit convenes more than 1,000 international diagnostic professionals for valuable networking and comprehensive programming spanning from clinical diagnostics to business strategy. Now in its eighth year, the event has grown to include novel immunotherapy biomarkers, cell-free DNA, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, commercialization and reimbursement.  For more information please visit www.nextgenerationdx.com.

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-next-generation-dx-summit-300315242.html

SOURCE Biocept, Inc.